60979-25-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-4-methoxybenzonitrile is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs and medicinal compounds. Its unique chemical structure allows it to be a key component in creating a variety of therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Amino-4-methoxybenzonitrile is utilized as a building block in the synthesis of agrochemicals, playing a crucial role in the development of pesticides and other agricultural chemicals that are essential for crop protection and yield enhancement.
Used in Dye and Pigment Production:
3-Amino-4-methoxybenzonitrile is used as an intermediate in the production of dyes and pigments, enabling the creation of a wide range of colorants for various applications, including textiles, plastics, and printing inks.
Used in Organic Compound Synthesis:
3-Amino-4-methoxybenzonitrile is also used as an intermediate in the synthesis of other organic compounds, highlighting its versatility in organic chemistry and its potential applications in various industries that rely on organic synthesis for product development.

InChI:InChI=1/C8H8N2O/c1-11-8-3-2-6(5-9)4-7(8)10/h2-4H,10H2,1H3

Upstream product

• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 124-41-4 sodium methylate 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 874-90-8 4-methoxybenzonitrile 
• 33224-23-6 4-Cyano-2-nitroanisol 

Downstream Products

• 1201666-79-6 3-azido-4-methoxybenzonitrile 
• 1110813-31-4 Dacomitinib 
• 17481-27-5 3-amino-4-methoxybenzamide 
• 1377582-30-3 (5-cyano-2-methoxy-phenyl)-thiourea 
• 1377582-29-0 3-Isothiocyanato-4-methoxy-benzonitrile 
• 1220628-02-3 6-((5-cyano-2-methoxyphenyl)amino)-8-((2,2,2-trifluoroethyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile 
• 857554-01-9 3-acetylamino-4-methoxy-benzonitrile 
• 65448-82-0 (5-cyano-2-methoxy-phenyl)-carbamic acid ethyl ester 

Relevant academic research and scientific papers

New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

New drugs against visceral leishmaniasis with mechanisms of action differing from existing treatments and with adequate cost, stability, and properties are urgently needed. No antitubulin drug is currently in the clinic against Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean area. We have designed and synthesized a focused library of 350 compounds against the Leishmania tubulin based on the structure-activity relationship (SAR) and sequence differences between host and parasite. The compounds synthesized are accessible, stable, and appropriately soluble in water. We assayed the library against Leishmania promastigotes, axenic, and intracellular amastigotes and found 0, 8, and 16 active compounds, respectively, with a high success rate against intracellular amastigotes of over 10%, not including the cytotoxic compounds. Five compounds have a similar or better potency than the clinically used miltefosine. 14 compounds showed a host-dependent mechanism of action that might be advantageous as it may render them less susceptible to the development of drug resistance. The active compounds cluster in five chemical classes that provide structure-activity relationships for further hit improvement and facilitate series development. Molecular docking is consistent with the proposed mechanism of action, supported by the observed structure-activity relationships, and suggests a potential extension to other Leishmania species due to sequence similarities. A new family of diarylsulfonamides designed against the parasite tubulins is active against Leishmania infantum and represents a new class of potential drugs with favorable cost, stability, and aqueous solubility for the treatment of visceral leishmaniasis (VL). These results could be extended to other clinically relevant species of Leishmania spp.

Photocatalytic C-H Amination of Aromatics Overcoming Redox Potential Limitations

We report the photocatalytic C-H amination of aromatics overcoming redox potential limitations. Radical cations of aromatic compounds are generated photocatalytically using Ru(phen)3(PF6)2, which has a reduction potential at a high oxidation state (Ered(RuIII/RuII) = +1.37 V vs SCE) lower than the oxidation potentials of aromatic substrates (Eox = +1.65 to +2.27 V vs SCE). The radical cations are trapped with pyridine to give N-arylpyridinium ions, which were converted to aromatic amines.

Pyridyl Radical Cation for C?H Amination of Arenes

Electron-transfer photocatalysis provides access to the elusive and unprecedented N-pyridyl radical cation from selected N-substituted pyridinium reagents. The resulting C(sp2)?H functionalization of (hetero)arenes furnishes versatile intermediates for the development of valuable aminated aryl scaffolds. Mechanistic studies that include the first spectroscopic evidence of a spin-trapped N-pyridyl radical adduct implicate SET-triggered, pseudo-mesolytic cleavage of the N?X pyridinium reagents mediated by visible light.

Direct and practical synthesis of primary anilines through iron-catalyzed C-H bond amination

The direct C-H amination of arenes is an important strategy to streamline the discovery and preparation of functional molecules. Herein, we report an operationally simple arene C-H amination reaction that, in contrast to most literature precedent, affords directly the synthetically versatile primary aniline products without relying on protecting group manipulations. Inexpensive Fe(II)-sulfate serves as a convenient catalyst for the transformation. The reaction tolerates a wide scope of arenes, including structurally complex drugs. Importantly, the arene substrates are used as limiting reagents in the transformation. This operationally simple transformation should considerably accelerate the discovery of medicines and functional molecules.

PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BENZOTHIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to benzothiazole (formula I) and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated an

Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3- triazoles

Novel dicationic triazoles 1-60 were synthesized by the Pinner method from the corresponding dinitriles, prepared via the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The type and the placement of cationic moieties as well as the nature of arom

BENZOPYRAN DERIVATIVES

Benzopyran derivatives (I) (R = phenyl, alkoxycarbonyl, alkylcarbonyl, CONH2, CONH(alkyl), CON(alkyl)2, CN or alkoxycarbonylamino; R2 = alkyl, alkoxy, polyfluoroalkoxy, OH or CF3SO2O; each of R4 and R5 independently = H, halogen, polyfluoroalkyl, polyfluo

Benzopyran derivatives

The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.